The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2024

Filed:

Mar. 14, 2019
Applicant:

The Governors of the University of Alberta, Edmonton, CA;

Inventors:

Michael Houghton, Danville, CA (US);

Abdolamir Landi, Edmonton, CA;

Michael Logan, Edmonton, CA;

John L. Law, Edmonton, CA;

Chao Chen, Edmonton, CA;

Darren Hockman, Edmonton, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/29 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); A61P 37/04 (2006.01);
U.S. Cl.
CPC ...
A61K 39/29 (2013.01); A61P 31/14 (2018.01); A61P 37/04 (2018.01); A61K 2039/55505 (2013.01); C12N 2770/24222 (2013.01); C12N 2770/24234 (2013.01);
Abstract

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a 'T-cell epitope polypeptide' or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4and CD8T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.


Find Patent Forward Citations

Loading…